Table 1.
Baseline patient demographics, medications, co-morbidites, and SSc-specific characteristics for systemic sclerosis patients and non-SSc controls.
| Scleroderma N=138 | Controls N=40 | p-value | |
|---|---|---|---|
| Age (years), mean ± SD | 54.3 ± 12.6 | 53.5 ± 14 | 0.704 |
| Women, no. (%) | 121 (87.7) | 35 (87.7) | 0.976 |
| Race, no. (%), N=137 for scleroderma | NA | ||
| White | 104 (75.9) | ||
| Black | 27 (19.7) | ||
| Other | 6 (4.4) | ||
| Hypertension, no. (%) | 50 (36.2) | NA | |
| Diabetes Mellitus, no. (%) | 9 (6.5) | NA | |
| Atherosclerotic cardiovascular disease* | 9 (6.5) | NA | |
| Atrial Fibrillation, no. (%) | 3 (2.2) | NA | |
| Ever Smoker, no. (%) | 55 (39.9) | 15 (37.5) | 0.788 |
| Vasodilator Medications, no. (%) | NA | ||
| Calcium Channel Blockers | 61 (44.2) | ||
| Phosphodiesterase 5 inhibitors | 15 (10.9) | ||
| Endothelin Receptor Antagonists | 3 (2.2) | ||
| Prostacyclin analogs | 0(0) | ||
| Scleroderma disease duration (years), median (interquartile range) | 13.5 (6.7, 22.4) | NA | |
| Scleroderma subtype, no. (%) | NA | ||
| Limited | 83 (60.1) | ||
| Diffuse | 55 (39.9) | ||
| Autoantibody status, no. (%) | NA | ||
| ANA, n=138 | 135 (98.7) | ||
| Centromere, n=137 | 40 (29.2) | ||
| Topoisomerase 1, n=136 | 38 (27.9) | ||
| RNA polymerase III, n=115 | 19 (16.5) | ||
| Pulmonary function data, mean ± SD | NA | ||
| Forced vital capacity (% predicted), N=134 SSc | 82.5 (18.5) ± 1.6 | ||
| Diffusing capacity (% predicted), N=132 SSc | 81.4 (25.4) ± 2.21 |
*
Defined by presence of peripheral arterial disease and/or coronary artery disease. NA= Not applicable or not available